Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Xeris Biopharma Holdings Inc XERS

Healthcare
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:XERS)

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire April 3, 2024

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

Business Wire March 6, 2024

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

Business Wire March 6, 2024

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Business Wire February 28, 2024

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

Business Wire February 5, 2024

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

Business Wire January 10, 2024

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire January 5, 2024

Xeris Biopharma Updates Its Outlook for 2023

Business Wire January 4, 2024

Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire December 27, 2023
View More News ››

Opinion & Analysis (NDAQ:XERS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:XERS)

GOING UP and NO ONE HERE

sh NOOBs are still fretting away on FAILED stock promos lol lol
WakeUPP - June 25, 2021
View more Bullboard ››

Geologica Resource Corp.

Geologica Resource Corp.

Geologica Resource Corp. is an exploration and development company focused on the acquisition, exploration and development of ...
View More »